KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Acquisitions & Divestments: 2020-2025

Historic Change in Acquisitions & Divestments for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $93.5 million.

  • Aurinia Pharmaceuticals' Change in Acquisitions & Divestments fell 29.47% to $93.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $472.8 million, marking a year-over-year decrease of 21.15%. This contributed to the annual value of $585.4 million for FY2024, which is 10.59% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Change in Acquisitions & Divestments stood at $93.5 million, which was down 29.30% from $132.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $170.5 million in Q1 2024 and a low of $60.9 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $132.2 million (2025), whereas its average is $133.1 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 325.13% in 2021, and later dropped by 29.47% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Change in Acquisitions & Divestments stood at $90.7 million in 2021, then spiked by 30.36% to $118.2 million in 2022, then rose by 16.82% to $138.1 million in 2023, then decreased by 10.22% to $124.0 million in 2024, then declined by 29.47% to $93.5 million in 2025.
  • Its last three reported values are $93.5 million in Q3 2025, $132.2 million for Q2 2025, and $123.0 million during Q1 2025.